{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:15:09Z","timestamp":1764731709421},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Men diagnosed with prostate cancer are at risk for competing morbidity and mortality due to cardiometabolic disease given their advanced age at diagnosis, high prevalence of pre-existing risk factors, and receipt of systemic therapy that targets the androgen receptor (AR). Expert panels have stressed the importance of cardiometabolic risk assessment in the clinic and proposed evaluating key risks using consensus paradigms. Yet, there is a gap in real-world evidence for implementation of comprehensive cardiometabolic care for men with prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective, descriptive study of patients with prostate cancer who were referred and evaluated in the Healthy Heart Program at MD Anderson Cancer Center, which was established to mitigate cardiometabolic risks in men with prostate cancer. Patients were seen by a cardiologist and exercise physiologist to evaluate and manage cardiometabolic risk factors, including blood pressure, cholesterol, blood glucose, tobacco use, and coronary artery disease, concurrent with management of their cancer by a medical oncologist.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From December 2018 through October 2021, the Healthy Heart Program enrolled 55 men with prostate cancer, out of which 35 had biochemical, locoregional recurrence or distant metastases, while all received at least a single dose of a luteinizing hormone-releasing hormone (LHRH) analog. Ninety-three percent of men were overweight or obese, and 51% had an intermediate or high risk of atherosclerotic cardiovascular disease at 10\u00a0years based on the pooled cohort equation. Most men had an overlap of two or more cardiometabolic diseases (84%), and 25% had an overlap of at least 4 cardiometabolic diseases. Although uncontrolled hypertension and hyperlipidemia were common among the cohort (45% and 26%, respectively), only 29% of men followed up with the clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Men with prostate cancer have a high burden of concurrent cardiometabolic risk factors. At a tertiary cancer center, the Healthy Heart Program was implemented to address this need, yet the utility of the program was limited by poor follow-up possibly due to outside cardiometabolic care and inconvenient appointment logistics, a lack of cardiometabolic labs at the time of visits, and telemedicine visits.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40959-023-00186-x","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T04:01:35Z","timestamp":1694577695000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience"],"prefix":"10.1186","volume":"9","author":[{"given":"Andrew W.","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whittney","family":"Thoman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Basen-Enngquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"issue":"15","key":"186_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1606220. (In eng).","journal-title":"N Engl J Med"},{"issue":"28","key":"186_CR2","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1200\/jco.21.02517","volume":"40","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Tangen CM, Hussain MHA, et al. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022;40(28):3301\u20139. https:\/\/doi.org\/10.1200\/jco.21.02517. (In eng).","journal-title":"J Clin Oncol"},{"issue":"1","key":"186_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708. (In eng).","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"186_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1200\/JOP.18.00178","volume":"14","author":"D Gupta","year":"2018","unstructured":"Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580\u20137. https:\/\/doi.org\/10.1200\/JOP.18.00178.","journal-title":"J Oncol Pract"},{"issue":"4","key":"186_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaccao.2020.08.011","volume":"2","author":"J Gong","year":"2020","unstructured":"Gong J, Payne D, Caron J, et al. Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer. JACC CardioOncol. 2020;2(4):553\u201363. https:\/\/doi.org\/10.1016\/j.jaccao.2020.08.011. (In eng).","journal-title":"JACC CardioOncol"},{"issue":"12","key":"186_CR6","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/jco.2005.04.7423","volume":"24","author":"UE Studer","year":"2006","unstructured":"Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(12):1868\u201376. https:\/\/doi.org\/10.1200\/jco.2005.04.7423. (In eng).","journal-title":"J Clin Oncol"},{"issue":"1","key":"186_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/pcan.2011.55","volume":"15","author":"S Shikanov","year":"2012","unstructured":"Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012;15(1):106\u201310. https:\/\/doi.org\/10.1038\/pcan.2011.55. (In eng).","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"186_CR8","doi-asserted-by":"publisher","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","volume":"4","author":"AO Elmehrath","year":"2021","unstructured":"Elmehrath AO, Afifi AM, Al-Husseini MJ, et al. Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016. JAMA Netw Open. 2021;4(8):e2119568 (In eng).","journal-title":"JAMA Netw Open"},{"issue":"6","key":"186_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/circulationaha.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121(6):833\u201340. https:\/\/doi.org\/10.1161\/circulationaha.109.192695. (In eng).","journal-title":"Circulation"},{"issue":"5","key":"186_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/circulationaha.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016;133(5):537\u201341. https:\/\/doi.org\/10.1161\/circulationaha.115.012519. (In eng).","journal-title":"Circulation"},{"issue":"2","key":"186_CR11","doi-asserted-by":"publisher","first-page":"e210070","DOI":"10.1001\/jamanetworkopen.2021.0070","volume":"4","author":"L Sun","year":"2021","unstructured":"Sun L, Parikh RB, Hubbard RA, et al. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. JAMA Netw Open. 2021;4(2):e210070 (In eng).\u00a0https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0070","journal-title":"JAMA Netw Open."},{"issue":"8","key":"186_CR12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/circulationaha.118.035550","volume":"139","author":"SAE Peters","year":"2019","unstructured":"Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016. Circulation. 2019;139(8):1025\u201335. https:\/\/doi.org\/10.1161\/circulationaha.118.035550. (In eng).","journal-title":"Circulation"},{"key":"186_CR13","doi-asserted-by":"publisher","unstructured":"Parikh M, Robles D, Pan C-x, et al. Results from a phase Ib\/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC). J Clin Oncol 2019;37(15_suppl):5054\u20135054.\u00a0https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.5054.","DOI":"10.1200\/JCO.2019.37.15_suppl.5054"},{"key":"186_CR14","doi-asserted-by":"publisher","unstructured":"Logothetis CJ, Hahn AW. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2023 (In eng).\u00a0https:\/\/doi.org\/10.1016\/j.eururo.2023.04.015.","DOI":"10.1016\/j.eururo.2023.04.015"},{"issue":"1","key":"186_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijrobp.2018.07.2018","volume":"103","author":"JA Holmes","year":"2019","unstructured":"Holmes JA, Anderson RF, Hoffman LG, et al. Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective Study. Int J Radiat Oncol Biol Phys. 2019;103(1):112\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2018. (In eng).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"186_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.urolonc.2019.10.006","volume":"38","author":"V Narayan","year":"2020","unstructured":"Narayan V, Harrison M, Cheng H, et al. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020;38(3):83\u201393. https:\/\/doi.org\/10.1016\/j.urolonc.2019.10.006. (In eng).","journal-title":"Urol Oncol"},{"issue":"25","key":"186_CR17","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/cir.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/cir.0000000000000625. (In eng).","journal-title":"Circulation"},{"issue":"16","key":"186_CR18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/circulationaha.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation. 2021;144(16):1295\u2013307. https:\/\/doi.org\/10.1161\/circulationaha.121.056810. (In eng).","journal-title":"Circulation"},{"issue":"6","key":"186_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/ju.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong DP, Fradet V, Shayegan B, et al. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. J Urol. 2020;203(6):1109\u201316. https:\/\/doi.org\/10.1097\/ju.0000000000000714. (In eng).","journal-title":"J Urol"},{"issue":"5","key":"186_CR20","doi-asserted-by":"publisher","first-page":"e022899","DOI":"10.1136\/bmjopen-2018-022899","volume":"8","author":"RU Newton","year":"2018","unstructured":"Newton RU, Kenfield SA, Hart NH, et al. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open. 2018;8(5):e022899 (In eng).","journal-title":"BMJ Open"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-023-00186-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-023-00186-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-023-00186-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T01:38:30Z","timestamp":1700444310000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-023-00186-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1186\/s40959-023-00186-x","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Texas MD Anderson Cancer Center Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AWH reports advisory board consultation for Janssen and Intellisphere, honoraria from Medscape, and travel support from Dava Oncology. WT, AA, and EK have no conflicts of interest to disclose. SCG currently is employed by Labcorp Drug Development and is a consultant for Moving Analytics which is a virtual cardiac rehabilitation program. SCG has no conflicts of interest to disclose for this manuscript. CJL reports advisory board consultation for Merck, Sharpe & Dohme, Exelixis, Bayer, and Amgen; honoraria from Bayer and Amgen; and institutional funding from Janssen, ORIC Pharmaceuticals, Novartis, and Aragon Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}